MacroGenics | MGNX - Ordinary Share Capital


MacroGenics reported $63.56M in Ordinary Share Capital for its fiscal quarter ending in March of 2026.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Amgen USD 541M 1000K Jun/2026
AstraZeneca USD 1.55B 44K Jun/2026
Biogen USD 146.7M 200K Sep/2025
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Daiichi Sankyo JPY 1.82B 30.68M Jun/2026
Eli Lilly USD 943.5M 3.33M Mar/2026
Genmab DKK 61.44M 181K Jun/2026
Geron USD 640.9M 2.54M Mar/2026
Gilead Sciences USD 1.24B 1000K Jun/2026
J&J USD 2.41B 1.35M Mar/2026
Karyopharm Therapeutics USD 22.54M 4.23M Mar/2026
MacroGenics USD 63.56M 241K Mar/2026
Merck USD 2.47B 4.93M Mar/2026
Pfizer USD 5.7B 0 Jun/2026
Puma Biotechnology USD 5K 0 Jun/2024
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Roche Holding CHF 796.77M 1.15M Jun/2026
Xencor USD 74.33M 265K Jun/2026